Special Issue

Gene Delivery Nanosystems

Message from the Guest Editor

The number of gene therapy clinical trials and approved gene therapy products has steadily increased in recent years. Substantial progress has been made in the development of different types of nucleic acids, including plasmid DNA, mRNA, microRNA, small interfering RNA, and antisense oligonucleotides, in order to use them in gene therapy approaches. Up to now, the large majority of gene therapy clinical trials has been based on the use of viral vectors, due to their features such as high levels of transduction or their efficient and stable integration of exogenous DNA into the host genome. Nonetheless, they have several drawbacks such as immunogenicity, limited DNA packaging capacity, challenging vector modification and/or production, and the possible activation of oncogenes. In this context, non-viral gene delivery systems, namely nanosystems, have the potential to overcome these limitations, allowing not only a safe but also an efficient gene delivery process into target cells. I would like to invite you to submit your original papers or reviews on the design, development, characterization, and application of nanosystems in nucleic acid delivery.

Guest Editor

Dr. Henrique Faneca

Center for Neuroscience and Cell Biology, University of Coimbra, 3004-517 Coimbra, Portugal

Deadline for manuscript submissions

closed (20 May 2025)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/223170

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

